Observational studyBMC nephrology2024
SGLT-2 inhibitors in chronic peritoneal dialysis patients: a follow-up study.
Observational study in BMC nephrology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Clinical rationale behind glucose-sparing strategies in peritoneal dialysis: a narrative review.BMC nephrology · 2026Review
- SGLT2 inhibitors in hemodialysis or peritoneal dialysis patients: rationale and state-of-the art.Clinical kidney journal · 2026Review
- Empagliflozin and Ultrafiltration Volume in Patients Undergoing Peritoneal Dialysis.Kidney international reports · 2026Article
- Sodium-Glucose Cotransporter 2 Inhibitor Use in Adults Undergoing Peritoneal Dialysis: A Propensity-Matched Real-World Data Analysis.Journal of clinical medicine · 2025Article
- Chronic cardiorenal syndrome: cardio-renal protective effect of SGLT2i.Renal failure · 2025Review
- Glycemic Control in Patients with Diabetes on Peritoneal Dialysis: From Glucose Sparing Approach to Glucose Monitoring.Life (Basel, Switzerland) · 2025Review
- Analysis of risk factors and application of risk management strategies in hemodialysis patients complicated with heart failure.Frontiers in cardiovascular medicine · 2025Article
- Benefits of SGLT2 inhibitors in patients with diabetes and advanced chronic kidney disease - where have we gone so far?Frontiers in clinical diabetes and healthcare · 2025Review
- Dapagliflozin May Increase Ultrafiltration and Urine Volume in Nondiabetic Peritoneal Dialysis Patients: A Case Series Report.Case reports in nephrology and dialysisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundSodium-glucose transporter-2 inhibitors (SGLT-2i) are recommended for use in patients with type 2 diabetes comorbid atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease. Limited reports are currently available for their use in dialysis patients. In an observational, retrospective follow-up study, we reported the clinical characteristics of chronic peritoneal dialysis (PD) patients on SGLT-2i.
methodsWe enrolled 50 diabetic chronic PD patients, and 11 continued SGLT-2i after PD treatment. We reported the patients' ultrafiltration, HbA1c, urinary tract infection episodes, and venous CO2 during follow-up and compared the differences in these factors between patients with and without SGLT-2i.
resultsThe mean age of the patients was 65 ± 15 years, and 16 (32%) patients were female. The age, gender, heart failure, and primary kidney disease were not different between patients with and without SGLT-2i at enrollment. In an average of 31 months follow-up, patients with SGLT-2i had higher ultrafiltration (1322 ± 200 ml/day vs. 985 ± 415 ml/day, p = 0.013), hemoglobin (11.2 ± 1.7 vs. 10.2 ± 1.7 g/dl), white blood cell count (9.2 ± 3.7 vs. 7.4 ± 2.1 10
conclusionSGLT-2i may increase ultrafiltration volume and hemoglobin levels in chronic PD patients. SGLT-2i did not increase urinary tract infection but was linked to subclinical metabolic acidosis. WHAT WAS KNOWN: The effect of SGLT-2i in chronic PD patients is not clear? THIS STUDY ADDS: SGLT-2i is associated with increased ultrafiltration, hemoglobin, white blood cell counts, and a decreased CO2 in PD patient. POTENTIAL IMPACT: SGLT-2i may increase ultrafiltration in PD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.